Tumor Lysis Syndrome Management

Clinical Manifestations

• The American Society of Hematology recommends that tumor lysis syndrome be identified by the presence of at least 2 of the following 4 metabolic derangements: hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia, which can occur within 3 days before or 7 days after chemotherapy initiation 1
• Hyperuricemia can cause uric acid crystallization in renal collecting ducts, leading to acute oliguric renal failure, with a uric acid level of >8 mg/dL in adults 2, 1
• Hyperkalemia, with a level of ≥6 mmol/L, is life-threatening and can occur from rapid release of intracellular potassium, exacerbated by concurrent renal failure that impairs potassium excretion 3, 1
• Hyperphosphatemia develops from tumor cell lysis and can precipitate with calcium, worsening renal injury, with a level of >1.62 mmol/L requiring treatment 4, 1
• Hypocalcemia results from calcium-phosphate precipitation in tissues, with symptomatic hypocalcemia requiring treatment with calcium gluconate 50-100 mg/kg IV over 2-5 minutes 4, 1

High-Risk Features Requiring Vigilance

• Patients with bulky disease, elevated LDH >2 times upper normal limit, high white blood cell counts >50,000/mm³, pre-existing renal impairment, baseline hyperuricemia >8 mg/dL in children or >10 mg/dL in adults, and highly chemosensitive malignancies, including Burkitt's lymphoma and B-cell acute lymphoblastic leukemia, face substantially elevated TLS risk and warrant aggressive prophylaxis 5, 2
• The mortality rate in solid tumors approaches 35% due to delayed recognition and less aggressive prophylactic measures compared to hematologic malignancies 5, 2

Immediate Management Priorities

• The European Society for Medical Oncology recommends aggressive IV hydration at 3 L/m²/day to maintain urine output ≥100 mL/hour, and rasburicase 0.20 mg/kg/day IV over 30 minutes to rapidly convert uric acid to allantoin, achieving uric acid ≤2 mg/dL in 96% of patients within 4 hours 5, 2, 6
• For severe hyperkalemia (≥6 mmol/L), immediate interventions include calcium carbonate 100-200 mg/kg/dose IV to stabilize myocardial cell membranes, rapid insulin 0.1 units/kg IV plus 25% dextrose 2 mL/kg IV to shift potassium intracellularly, and continuous ECG monitoring 4, 3, 1

Indications for Emergency Hemodialysis

• The American Society of Nephrology recommends initiating hemodialysis urgently when oliguria or anuria persists despite aggressive hydration, severe refractory hyperkalemia is unresponsive to medical management, symptomatic hypocalcemia is refractory to treatment, severe hyperphosphatemia occurs with calcium-phosphate precipitation, or hyperuricemia is unresponsive to rasburicase 4, 1, 3
• Hemodialysis achieves uric acid clearance of 70-100 mL/min, reducing plasma uric acid by approximately 50% with each 6-hour treatment, often restarting diuresis when levels fall to 10 mg/dL 4

Monitoring Requirements

• Intensive laboratory monitoring is essential, with potassium levels checked every 2-4 hours after initial treatment, and uric acid, electrolytes, phosphate, and calcium levels checked every 6 hours for the first 24 hours 1
• Continuous ECG monitoring is mandatory for all patients with hyperkalemia 4

Clinical Presentation and Laboratory Criteria of Tumor Lysis Syndrome

Clinical Manifestations

• Patients receiving cytoreductive therapy commonly develop nausea, vomiting, diarrhea, anorexia, lethargy, edema, fluid overload, hematuria, congestive heart failure, cardiac dysrhythmias, seizures, muscle cramps, tetany, syncope, and may experience sudden death, typically within 12–72 hours after therapy initiation. 7
• Hyperkalemia (≥6 mmol/L) precipitates cardiac arrhythmias, ventricular tachycardia, fibrillation, or cardiac arrest, representing a life‑threatening cardiac manifestation of TLS. 8
• Fluid overload can lead to congestive heart failure in TLS patients. 7
• In a Burkitt’s lymphoma cohort, two of four deaths were directly attributable to hyperkalemia‑related sudden death. 9
• Elevated potassium levels cause muscle cramps and paresthesias. 7
• Symptomatic hypocalcemia produces tetany and seizures. 8
• Lethargy and syncope are reported neurological symptoms of TLS. 7
• Renal complications include hematuria, oliguria, and acute renal failure due to uric‑acid crystal deposition. 7
• Uremia arises from combined mechanisms such as uric‑acid crystals, calcium‑phosphate precipitation, and xanthine crystallization. 7

Laboratory Abnormalities

• Hyperuricemia (>8 mg/dL in adults) results from massive nucleic‑acid breakdown and can cause uric‑acid crystallization in renal collecting ducts, leading to acute oliguric renal failure. 7
• Hyperphosphatemia (>1.62 mmol/L) occurs after tumor cell lysis and may precipitate with calcium, aggravating renal injury. 10
• Hypocalcemia develops secondary to calcium‑phosphate precipitation in tissues and may be symptomatic with tetany or seizures. 10

Definition of Laboratory TLS

• Laboratory TLS is defined by the presence of two or more abnormal serum values (uric acid, potassium, phosphate, or calcium) occurring within 3 days before or 7 days after the start of chemotherapy. 9

Timing of Symptom Onset

• Clinical TLS symptoms most frequently appear within 12–72 hours after initiation of cytoreductive therapy, although spontaneous TLS can manifest before chemotherapy begins. 7

Mortality and Critical Risks

• When significant complications develop, the mortality rate for clinical TLS reaches approximately 83 %; without clinical TLS, mortality is about 24 %. (Evidence strength not specified)
• In solid tumors, delayed recognition of TLS is associated with mortality approaching 35 %. (Evidence strength not specified)
• Hyperkalemia can progress rapidly from mild symptoms (muscle cramps, palpitations) to life‑threatening arrhythmias and sudden cardiac death, underscoring the need for continuous ECG monitoring in affected patients. 8

Laboratory Diagnosis and Risk Assessment for Tumor Lysis Syndrome

Core Metabolic Abnormalities

• Hyperuricemia is defined as a serum uric acid concentration > 8 mg/dL (> 476 µmol/L) in adults. [11][12]
• Hyperuricemia results from rapid catabolism of purine nucleic acids via hypoxanthine and xanthine to uric acid through xanthine oxidase. 13
• When uric acid concentrations exceed ~15 mg/dL in the acidic environment of the distal renal tubule (pH ≈ 5), crystals precipitate, leading to acute oliguric renal failure. 13

• Patients with a baseline uric acid ≥ 8 mg/dL have an 11.7‑fold higher relative risk of developing TLS compared with those whose baseline is < 4 mg/dL. 13

• Hyperkalemia is defined as a serum potassium concentration ≥ 6.0 mmol/L (≥ 6 mEq/L). 11

• Elevated potassium can precipitate life‑threatening cardiac arrhythmias, including ventricular tachycardia, fibrillation, or cardiac arrest. 13

• Hyperphosphatemia is defined as a serum phosphorus concentration > 1.45 mmol/L (4.5 mg/dL) in adults or > 2.1 mmol/L (6.5 mg/dL) in children. 11

• Phosphate released from lysed tumor cells can combine with calcium, forming calcium‑phosphate crystals that deposit in renal tubules and exacerbate kidney injury. 13

• Hypocalcemia is defined as a serum calcium concentration ≤ 1.75 mmol/L (7 mg/dL). 11

Diagnostic Criteria

• Laboratory TLS is diagnosed when ≥ 2 of the above metabolic abnormalities occur within 3 days before to 7 days after the start of anticancer therapy, or when each parameter rises > 25 % from a recent baseline. 11

• Clinical TLS is defined as laboratory TLS plus at least one clinical complication such as renal failure (estimated GFR ≤ 60 mL/min), cardiac arrhythmia, or seizure. 11

Renal Function Assessment

• An elevated serum creatinine ≥ 1.5 times the upper limit of normal signals renal insufficiency in TLS. 12
• Estimated GFR calculated with the MDRD or Cockcroft‑Gault equations provides a more reliable assessment of renal function than serum creatinine alone, because creatinine is influenced by age, hydration, and muscle mass. 11

Timing of Laboratory Abnormalities

• Metabolic derangements most commonly manifest 12–72 hours after initiation of cytoreductive therapy; however, spontaneous TLS may occur before therapy in highly proliferative malignancies. 13

Clinical Monitoring Recommendation

• Do not rely solely on serum creatinine for renal assessment in TLS; always calculate eGFR to detect early acute kidney injury. 11